Last reviewed · How we verify
Budesonide pMDI HFA — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Budesonide pMDI HFA (Budesonide pMDI HFA) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Budesonide pMDI HFA TARGET | Budesonide pMDI HFA | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Budesonide pMDI HFA CI watch — RSS
- Budesonide pMDI HFA CI watch — Atom
- Budesonide pMDI HFA CI watch — JSON
- Budesonide pMDI HFA alone — RSS
Cite this brief
Drug Landscape (2026). Budesonide pMDI HFA — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-pmdi-hfa. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab